Pearce WJ, Williams JM, White CR, Lincoln TM. Effects of chronic hypoxia on soluble guanylate cyclase activity in fetal and adult ovine cerebral arteries. J Appl Physiol 107: 192-199, 2009. First published April 30, 2009 doi:10.1152/japplphysiol.00233.2009.-A broad variety of evidence obtained largely in pulmonary vasculature suggests that chronic hypoxia modulates vasoreactivity to nitric oxide (NO). The present study explores the general hypothesis that chronic hypoxia also modulates cerebrovascular reactivity to NO, and does so by modulating the activity of soluble guanylate cyclase (sGC), the primary target for NO in vascular smooth muscle. Pregnant and nonpregnant ewes were maintained at either sea level or at 3,820 m for the final 110 days of gestation, at which time middle cerebral arteries from term fetal lambs and nonpregnant adults were harvested. In both fetal and adult arteries, NO-induced vasodilatation was attenuated by chronic hypoxia and completely inhibited by 10 M 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a selective inhibitor of sGC. sGC abundance (in ng sGC/mg protein) measured via Western immunoblots was ϳ10-fold greater in fetal (17.6 Ϯ 1.6) than adult (1.7 Ϯ 0.3) arteries but was not affected by chronic hypoxia. The specific activity of sGC (in pmol cGMP ⅐ g sGC Ϫ1 ⅐ min Ϫ1 ) was similar in fetal (255 Ϯ 64) and adult (280 Ϯ 75) arteries and was inhibited by chronic hypoxia in both fetal (120 Ϯ 10) and adult (132 Ϯ 26) arteries. Rates of cGMP degradation (in pmol cGMP ⅐ mg protein Ϫ1 ⅐ min Ϫ1 ) were similar in fetal (159 Ϯ 59) and adult (134 Ϯ 36) arteries but were not significantly depressed by chronic hypoxia in either fetal (115 Ϯ 25) or adult (108 Ϯ 25) arteries. The cGMP analog 8-(p-chlorophenylthio)-cGMP was a more potent vasorelaxant in fetal (pD 2 ϭ 4.7 Ϯ 0.1) than adult (pD2 ϭ 4.3 Ϯ 0.1) arteries, but its ability to promote vasodilatation was not affected by chronic hypoxia in either age group. Together, these results reveal that hypoxic inhibition of NO-induced vasodilatation is attributable largely to attenuation of the specific activity of sGC and does not involve significant changes in sGC abundance, cGMP-phosphodiesterase activity, or the vasorelaxant activity of protein kinase G. cGMP; nitric oxide; phosphodiesterase; protein kinase G; smooth muscle THE ARTERIAL WALL is a heterogeneous composite of endothelial and smooth muscle cells, pericytes, perivascular nerves, fibroblasts, and patrolling leukocytes (3). This diverse assortment of cells is highly plastic, enabling the phenotypic characteristics of the various cell types to continuously change in response to physiological and pathophysiological stimuli (2). For example, during normal vessel development and postnatal maturation, overall artery hydration falls, protein content rises, and stiffness increases (45). In parallel, contractile capacity rises, as does responsiveness to both endothelium-dependent and endothelium-independent vasorelaxant stimuli (62). These physiological patterns of change, however, can be modulated or even reversed by pathophysiological stimuli, such as chronic hypoxia. Indeed, chronic hypoxia is one of the most potent of all vascular mitogens with diverse effects on both artery structure and contractility (48, 54) that are particularly pronounced in neonates (57). Functionally, chronic hypoxia antagonizes many patterns of normal vascular maturation and can result in reduced contractility and attenuated capacity for vasorelaxation (13, 32) .
nonpregnant ewes were maintained at either sea level or at 3,820 m for the final 110 days of gestation, at which time middle cerebral arteries from term fetal lambs and nonpregnant adults were harvested. In both fetal and adult arteries, NO-induced vasodilatation was attenuated by chronic hypoxia and completely inhibited by 10 M 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), a selective inhibitor of sGC. sGC abundance (in ng sGC/mg protein) measured via Western immunoblots was ϳ10-fold greater in fetal (17.6 Ϯ 1.6) than adult (1.7 Ϯ 0.3) arteries but was not affected by chronic hypoxia. The specific activity of sGC (in pmol cGMP ⅐ g sGC Ϫ1 ⅐ min Ϫ1 ) was similar in fetal (255 Ϯ 64) and adult (280 Ϯ 75) arteries and was inhibited by chronic hypoxia in both fetal (120 Ϯ 10) and adult (132 Ϯ 26) arteries. Rates of cGMP degradation (in pmol cGMP ⅐ mg protein Ϫ1 ⅐ min Ϫ1 ) were similar in fetal (159 Ϯ 59) and adult (134 Ϯ 36) arteries but were not significantly depressed by chronic hypoxia in either fetal (115 Ϯ 25) or adult (108 Ϯ 25) arteries. The cGMP analog 8-(p-chlorophenylthio)-cGMP was a more potent vasorelaxant in fetal (pD 2 ϭ 4.7 Ϯ 0.1) than adult (pD2 ϭ 4.3 Ϯ 0.1) arteries, but its ability to promote vasodilatation was not affected by chronic hypoxia in either age group. Together, these results reveal that hypoxic inhibition of NO-induced vasodilatation is attributable largely to attenuation of the specific activity of sGC and does not involve significant changes in sGC abundance, cGMP-phosphodiesterase activity, or the vasorelaxant activity of protein kinase G. cGMP; nitric oxide; phosphodiesterase; protein kinase G; smooth muscle THE ARTERIAL WALL is a heterogeneous composite of endothelial and smooth muscle cells, pericytes, perivascular nerves, fibroblasts, and patrolling leukocytes (3) . This diverse assortment of cells is highly plastic, enabling the phenotypic characteristics of the various cell types to continuously change in response to physiological and pathophysiological stimuli (2) . For example, during normal vessel development and postnatal maturation, overall artery hydration falls, protein content rises, and stiffness increases (45) . In parallel, contractile capacity rises, as does responsiveness to both endothelium-dependent and endothelium-independent vasorelaxant stimuli (62) . These physiological patterns of change, however, can be modulated or even reversed by pathophysiological stimuli, such as chronic hypoxia. Indeed, chronic hypoxia is one of the most potent of all vascular mitogens with diverse effects on both artery structure and contractility (48, 54) that are particularly pronounced in neonates (57) . Functionally, chronic hypoxia antagonizes many patterns of normal vascular maturation and can result in reduced contractility and attenuated capacity for vasorelaxation (13, 32) .
One of the most clinically relevant consequences of chronic hypoxia is persistent pulmonary hypertension of the neonate, which puts many infants at risk (1, 57) . Common therapeutic approaches to management of this pathology often involve inhalation of nitric oxide (NO) (15) and administration of phosphodiesterase inhibitors (53) , even though chronic hypoxia has long been known to depress reactivity to endotheliumdependent vasodilators and NO donors in the pulmonary vascular bed (13, 38) . Of particular importance is the growing recognition that standard treatments for persistent pulmonary hypertension can have very different effects in pulmonary and extrapulmonary vascular beds (38, 51, 59) and may even increase the risk for intracranial hemorrhage in premature infants (21, 51) . These findings and trends emphasize the importance of greater understanding of the effects of chronic hypoxia on the mechanisms mediating NO-dependent relaxation outside the pulmonary vasculature, and most particularly in the immature cerebral circulation (21) .
Previous work from our laboratory has demonstrated that postnatal maturation modulates many characteristics of vascular contractility (45) and depresses both the resting concentrations of cGMP (61) and the maximal rates of cGMP synthesis (60) in ovine cranial arteries. In addition, we have also shown that acclimatization to chronic hypoxia depresses NO-induced relaxation (32) as well as the release of NO from both the vascular endothelium (46) and from perivascular nitridergic nerves innervating cranial arteries (34) . Most recently, we have found that the inhibitory effects of chronic hypoxia on NOmediated vasorelaxation involve an age-dependent depression of soluble guanylate cyclase (sGC) activity in ovine common carotid arteries (64) . Together, these results strongly suggest that chronic hypoxia depresses reactivity to NO through multiple parallel mechanisms involving endothelial nitric oxide synthase (eNOS), neuronal NOS (nNOS), and sGC, at least in ovine carotid arteries. Equally important, the combined results suggest that effects of chronic hypoxia may vary significantly with postnatal age, particularly in relation to cGMP metabolism.
The present study explores the general hypothesis that in marked contrast to acute hypoxia (24), chronic hypoxia modulates cerebrovascular reactivity to NO by modulating the activity of sGC, the primary target for NO in vascular smooth muscle (9) . These studies expand our previous work and address four possible mechanisms through which such effects may occur in cerebral arteries: 1) decreased abundance of sGC, 2) decreased specific activity of sGC, 3) increased rates of cGMP degradation, or 4) decreased activation of protein kinase G-mediated vasorelaxation. In light of our previously documented effects of postnatal maturation on cGMP synthesis and metabolism (60, 61) , the experimental approach compares the responses from term fetal lambs and nonpregnant adult sheep and uses a combination of whole artery and broken cell methods that are well established in ovine cerebral arteries (61, 64) .
MATERIALS AND METHODS
All procedures used in these studies have been described in detail previously, were approved by the Animal Research Committee of Loma Linda University, and adhered to the policies and practices outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All homogenization protocols utilized mixed basilar, posterior communicating, and middle cerebral arteries taken from fetal (139 -142 days gestation) and young nonpregnant adult sheep (18 -24 mo old). Chronically hypoxic animals were maintained for Ϸ110 days at the Barcroft Laboratory, White Mountain Research Station (Bishop, CA; altitude 3,820 m). All contractility protocols used middle cerebral artery segments from which the endothelium was removed by passing a roughened needle through the lumen. Verification of denudation was determined by lack of vasorelaxation to 1 M bradykinin. Segments relaxing more than 10% after contraction with 1 M serotonin were excluded. All experiments were performed under ambient normoxic conditions, and the term "chronic hypoxia" refers to the high-altitude environment to which our chronically hypoxic animals were acclimatized before being euthanized.
NO-induced relaxation. To define the effects of chronic hypoxia and postnatal age on NO-induced relaxation, endothelium-denuded fetal and adult middle cerebral artery segments were cut into segments 3-5 mm in length and mounted on paired wires between a lowcompliance force transducer (Radnoti, Monrovia, CA) and a post attached to a micrometer used to vary resting tension, as previously described in detail (62) . Segments were equilibrated at least 1 h at 38.5°C (normal ovine core temperature) in a bicarbonate Krebs solution containing (in mM) 122 NaCl, 25.6 NaHCO 3, 5.56 dextrose, 5.17 KCl, 2.49 MgSO4, 1.60 CaCl2, 0.114 ascorbic acid, and 0.027 disodium EDTA, continuously bubbled with 95% O2-5% CO2. During equilibration, segments were maintained at optimum resting tensions as previously described. Following an initial stabilizing contraction by an isotonic potassium Krebs solution (122 mM K ϩ ), segments were contracted with 3 M serotonin. Following attainment of a stable level of initial tone, 10 M of the NO donor S-nitrosopenacillimine (SNAP) was added to the bath in either the presence or absence of 10 M 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ), a potent and specific inhibitor of sGC (18) . The vasorelaxation response was recorded continuously via online computer, and the maximum response observed within 3 min of application of SNAP was taken as the magnitude of the response.
sGC enzyme activity in artery homogenates. For each enzyme preparation, ϳ0.150 g wet weight of frozen artery segments was homogenized in 2 ml of ice-cold 50 mM Tris ⅐ HCl buffer (pH 7.5), containing 4 mM MgCl 2, and 2 mM D,L-dithiothreitol (DTT). The homogenization buffer also contained a mixture of protease inhibitors (76.8 nM aprotinin, 83 mM benzaminidine, 1 mM iodoacetamide, 1.1 M leupeptin, 7 M pepstatin A, and 0.23 mM phenylmethylsulfonyl fluoride). Homogenization was carried out at 4°C using a motordriven ground glass pestle and mortar. To separate particulate guanylate cyclase from sGC, homogenates were centrifuged for 60 min at 110,000 g, and then an aliquot of supernate was removed for protein determination. The remaining supernate was diluted using homogenization buffer to the desired protein concentration of 3 mg/ml Tris soluble protein. Fresh homogenate was prepared for each activity measurement.
The activity of sGC was determined by measuring the formation of cGMP from GTP in 200-l aliquots of the diluted artery homogenate. To remove endogenous cGMP and GTP from the preparation, sample tubes were warmed in a 38°C water bath for a minimum 30 min "clearing period." To prevent the hydrolysis of cGMP during the experimental procedure, a solution containing 1 mM 3-isobutyl-1-methylxanthine (IBMX) and 0.1 mM zaprinast was added to each tube after the clearing period and allowed to incubate for an additional 30 min. Reactions were initiated by the addition of GTP (0.02-1.0 mM final concentration) plus preformed nitrosylated heme (2 m final concentration) (3). The final reaction volume was 350 l. The samples were incubated for 5 or 15 min, after which 2 ml of ice-cold 6% trichloroacetic acid was added to each tube to stop the reaction. The samples were then centrifuged, ether extracted, lyophilized, and assayed for cGMP by radioimmunoassay.
Western immunoblotting for sGC protein.
Given that total tissue enzyme activity is influenced by enzyme abundance, samples obtained from the sGC enzyme assay were assayed for sGC protein abundance. Samples (20 g per lane) were separated on 10% polyacrylamide SDS gels, and the resulting band intensities were normalized against known masses of pure recombinant sGC enzyme (Alexis Chemical, San Diego, CA). The separated proteins were transferred to nitrocellulose using a current of 15 mA for 2.5 h in Towbin's buffer (25 mM Tris, 192 mM glycine, 20% methanol). Following transfer, the membranes were blocked with 2% milk, 2% BSA, and 0.1% Tween-20 in Tris-buffered saline (TBS) overnight at 4°C, then probed with a sGC polyclonal antibody (Cayman Chemical, Ann Arbor, MI) at 1:1,500 dilution in blocking buffer for 2 h. The membranes were then washed twice in blocking buffer for 15 min each and probed with a horseradish peroxidase-conjugated goat anti-rabbit antibody diluted 1:150,000. After 1 h of incubation with the second antibody, the membranes were washed as described for the first antibody followed by 5 min wash in TBS, and then the blots were visualized by using West Femto chemiluminescent substrate (Pierce, Rockford, IL) in a ChemiImager 4400, (Alpha Innotech, San Leandro, CA).
Rates of cGMP degradation in whole arteries. Because the rate of hydrolysis of cGMP has a major influence on the ability of cGMP, and in turn NO, to promote vasodilatation, we examined the effects of chronic hypoxia on phosphodiesterase-mediated degradation of cGMP in both fetal and adult arteries. Artery segments were mounted for contractility measurements as described above and then initially were contracted by exposure to an isotonic potassium Krebs solution (122 mM K ϩ ). After peak tensions were attained, segments were washed with normal sodium Krebs solution and allowed to return to baseline levels of tension for 30 min. Following an additional incubation for 30 min in the presence or absence of 300 M IBMX to inhibit phosphodiesterase activity, artery segments then were contracted with 3 M serotonin. Following attainment of a stable level of initial tone, segments were frozen in liquid nitrogen after 0, 15, 30, or 45 s of exposure to 10 M SNAP. The 300 M concentration of IBMX used was found to maximally inhibit phosphodiesterase activity in previous studies of ovine arteries (61) .
For determination of cGMP content, arteries were homogenized in 6% trichloroacetic acid, and the supernatants were washed with water-saturated diethyl ether, then lyophilized. The content of cGMP in each sample was then measured as described in MATERIALS AND METHODS for homogenized sGC enzyme activity. Levels of cGMP were normalized to base soluble protein obtained from trichloroacetic acid precipitates. All methods used for the quantitation of cGMP have been previously published in detail (61) .
8-(p-Chlorophenylthio)-cGMP dose-response studies.
To assess the effects of chronic hypoxia on cGMP-dependent vasorelaxation, dose-response studies with a cGMP analog were measured. Since cGMP does not easily cross the cell membrane and is rapidly metabolized on entering the cytosol, these studies employed the cGMP analog 8-(p-chlorophenylthio)-cGMP (8-pCPT-cGMP), a membranepermeable and nonmetabolizable molecule (8) . Artery segments were prepared as previously described. Following contraction by potassium Krebs solution, segments were contracted with 3 M serotonin. Following attainment of a stable level of initial tone, cumulative doses of 8-pCPT-cGMP were added to the baths to produce concentrations ranging from 10 Ϫ6 to 10 Ϫ2 M. Data analysis and statistics. Km and Vmax values were calculated by fitting the substrate-velocity data to the Michaelis-Menten equation. Rates of cGMP production in whole arteries were calculated from the slope values of cGMP content vs. time, obtained by a best-fit linear curve. Maximum relaxation responses were calculated as percentage relaxations of the maximum initial contractile tension. For determination of pD 2 (Ϫlog ED50), the relaxation data were normalized relative to maximum percentage relaxation and then fitted to the logistic equation using nonlinear regression as previously described (64) . Total phosphodiesterase activity was calculated as the difference in the rate of cGMP accumulation in the presence and absence of IBMX. All data were independently analyzed using a two-way ANOVA with oxygen level as one factor (normoxic vs. hypoxic) and maturation as the other (fetal vs. adult). Homoscedasticity was verified for all ANOVA comparisons using Bartlett's test. The individual effects of chronic hypoxia and maturation were determined by post hoc Duncan's tests. For all comparisons that were not significantly different, a minimum statistical power of 0.8 was attained.
RESULTS
In total, 352 arterial segments were obtained from 17 normoxic and 17 hypoxic adults and 25 normoxic and 48 hypoxic fetal sheep. When the same protocol was run using multiple segments of the same artery type from the same animal, the results were averaged by animal. Throughout the text, the given values of n refer to the number of animals studied and not the number of arterial segments.
NO-induced relaxation. The contractile tensions produced by addition of 3 M serotonin averaged 1.67 Ϯ 0.25 and 1.77 Ϯ 0.19 g in normoxic and hypoxic fetal arteries, respectively. Corresponding values in adult arteries averaged 3.06 Ϯ 0.40 and 2.90 Ϯ 0.46 g, respectively. Consistent with our previous findings in cerebral arteries (32) , chronic hypoxia did not significantly influence the contractile responses to 3 M serotonin. Addition of 10 M SNAP significantly relaxed contractile tone induced by 3 M serotonin in all artery groups (Fig. 1) . The average relaxation magnitudes were significantly greater in normoxic (91.4 Ϯ 1.6, n ϭ 12) than in hypoxic (74.2 Ϯ 4.5, n ϭ 10) adult middle cerebral arteries. Average relaxation magnitudes were also significantly greater in normoxic (85.9 Ϯ 3.7, n ϭ 13) than in hypoxic (71.4 Ϯ 3.6, n ϭ 9) fetal middle cerebral arteries. In all cases, 10 M ODQ eliminated the relaxation responses to 10 M SNAP.
Homogenate sGC enzyme activity. To evaluate the influence of chronic hypoxia on sGC enzyme kinetics, the activity of sGC was determined by the conversion of GTP to cGMP in cerebral arterial homogenates. Activation of sGC with NOheme in the presence of various GTP concentrations yielded cGMP formation that followed Michaelis-Menten kinetics (Fig. 2) . Homogenate V max values for sGC averaged 4.48 Ϯ 1.13 and 2.05 Ϯ 0.17 pmol cGMP ⅐mg protein Ϫ1 ⅐min Ϫ1 in normoxic and hypoxic fetal arteries, respectively, and these values were significantly greater than corresponding adult values (0.47 Ϯ 0.13 and 0.35 Ϯ 0.07, respectively). Chronic hypoxia also significantly depressed V max values when adult and fetal results were combined (ANOVA), but only in fetal cerebral arteries when the results were compared by post hoc analysis (Duncan's). Normoxic and hypoxic homogenate K m values for sGC averaged 0.090 Ϯ 0.030 and 0.086 Ϯ 0.015, respectively, in the adult, and these values were significantly greater than observed in normoxic (0.027 Ϯ 0.004 mM GTP) and hypoxic (0.047 Ϯ 0.007 mM GTP) fetal homogenates.
Abundance and specific activity of sGC in ovine cerebral arteries. To determine how chronic hypoxia influenced the abundance and specific activity of sGC, the content of sGC was measured in samples from the homogenate assays using a polyclonal antibody specific for sGC. To obtain absolute abundances, all homogenate values were calibrated against band densities obtained from varying known quantities of a purified exogenous sGC standard (Fig. 3, top) . Abundances of sGC protein averaged 1.7 Ϯ 0.3 and 2.7 Ϯ 0.5 ng sGC/mg protein in normoxic and hypoxic adult homogenates, respectively, and these values were significantly less than those observed in normoxic (17.6 Ϯ 1.6 ng sGC/mg protein) and hypoxic (17.1 Ϯ 1.4 ng sGC/mg protein ) fetal homogenates.
To assess how chronic hypoxia influenced the specific activity of sGC, the V max values obtained from the homogenate assays were normalized relative to sGC abundance, as measured with the Western blots, to calculate apparent enzyme specific activity (Fig. 3, bottom) in units of picomoles cGMP per microgram sGC per minute. Values of sGC apparent specific activity averaged 279.1 Ϯ 75.2 and 131.7 Ϯ 25.9 in adult and 255.1 Ϯ 64.4 and 119.6 Ϯ 9.6 in fetal artery homogenates in the normoxic and hypoxic groups, respectively. Chronic hypoxia significantly depressed sGC specific activity across both age groups (ANOVA), and this effect was also significant by post hoc analysis in both age groups.
Rates of cGMP degradation in whole arteries. Direct comparisons of rates of cGMP accumulation in the presence and absence of IBMX in adjacent segments from the same artery enabled the calculation of rates of total cGMP degradation. These values averaged 134 Ϯ 36 (n ϭ 5) and 108 Ϯ 25 (n ϭ 7) pmol cGMP ⅐mg protein Ϫ1 ⅐min Ϫ1 in normoxic and hypoxic adult arteries, respectively (Fig. 4) . Corresponding fetal values averaged 159 Ϯ 59 (n ϭ 7) and 115 Ϯ 25 (n ϭ 8). Although chronic hypoxia tended to depress rates of total cGMP degradation, this effect was not significant in either fetal or adult arteries.
8-pCPT-cGMP dose-response relations.
Aside from potential effects on cGMP synthesis, it is quite possible that chronic hypoxia could alter the ability of cGMP to promote vasorelaxation. To explore this possibility, relaxation responses to 8-pCPT-cGMP, a membrane-permeant and nonmetabolizable cGMP analog, were examined. In dose-response experiments, 8-pCPT-cGMP elicited dose-dependent relaxations in all arteries studied (Fig. 5) . Efficacy (E max ) values for 8-pCPT-cGMP averaged 99.3 Ϯ 0.7% and 98.0 Ϯ 1.2% (adult) and 99.2 Ϯ 0.6% and 100 Ϯ 0.0% (fetal) in normoxic and hypoxic arteries, respectively. Sensitivity to 8-pCPT-cGMP, as reflected by its pD 2 values, averaged 4.3 Ϯ 0.1 and 4.2 Ϯ 0.1 (adult) and 4.7 Ϯ 0.1 and 4.6 Ϯ 0.1 (fetal) in normoxic and hypoxic arteries, respectively. Thus sensitivity to 8-pCPT-cGMP was not influenced by chronic hypoxia but was enhanced in fetal compared with adult arteries; this effect was individually significant by post hoc analysis in both normoxic and hypoxic arteries (Fig.  5, insets) .
DISCUSSION
The results offer five main findings in ovine cerebral arteries: 1) NO-induced vasodilatation was attenuated by chronic hypoxia and completely inhibited by ODQ, a selective inhibitor of soluble guanylate cyclase; 2) soluble guanylate cyclase abundance was ϳ10-fold greater in fetal than adult arteries but was not affected by chronic hypoxia; 3) the specific activity of soluble guanylate cyclase was similar in fetal and adult arteries and was inhibited by chronic hypoxia in both age groups; 4) rates of cGMP degradation were not significantly depressed by chronic hypoxia; and 5) cGMP was a more potent vasorelaxant in fetal than adult arteries, but its ability to promote vasodilatation was not affected by chronic hypoxia in either age group. Fig. 3 . Effects of chronic hypoxia on sGC abundance and specific enzyme activity. sGC abundance values (top) were used to normalize homogenate velocities to estimate enzyme specific activity (bottom) for hypoxic and normoxic adult and fetal cerebral arteries. Maturation significantly depressed the abundance of sGC as revealed by factorial ANOVA. The effect of maturation was individually significant by post hoc Duncan's analysis in both normoxic and hypoxic arteries. Chronic hypoxia also significantly depressed enzyme specific activity in both fetal and adult arteries (*). F Significant age-related effects for corresponding treatments. Vertical error bars indicate SEs for 6 animals in each case. Consistent with previous findings in rat pulmonary (26) , sheep pulmonary (47) , and sheep cranial (63) arteries, NOinduced relaxation was attenuated by chronic hypoxia in both age groups (Fig. 1) . Because the vasorelaxant effects of NO were fully inhibited by ODQ, a well-characterized specific inhibitor of soluble guanylate cyclase (18) , cGMP-independent mechanisms of relaxation proposed to contribute to NO-induced vasodilatation (28, 36) probably played no significant role in our experiments. Similarly, because chronic hypoxia had no significant effect on the contractile tensions produced by 3 M serotonin in either fetal or adult arteries, the observed effects of chronic hypoxia on NO-induced relaxation cannot be attributed to an effect on the arteries' ability to develop contractile tone. Together, these results implicate a change in the tissue velocity of soluble guanylate cyclase as a possible mediator of chronic hypoxia-induced decreases in cerebrovascular reactivity to NO.
Homogenate measurements of soluble guanylate cyclase kinetics revealed several important differences (Fig. 2) . First, the total tissue velocity of soluble guanylate cyclase was significantly greater in fetal than adult preparations, consistent with previously reported findings (4, 60) . Second, the K m values for GTP were slightly but significantly less in fetal than adult artery homogenates but were unaffected by chronic hypoxia, suggesting minor age-related differences in soluble guanylate cyclase isoform (43, 49) , although the very low values obtained for K m suggest that these differences would be of minor physiological importance at typical intracellular concentrations of GTP, which are presumably near millimolar (7). Third, chronic hypoxia inhibited the maximal tissue velocity of soluble guanylate cyclase, and this effect was particularly prominent in the fetal artery homogenates. These results, in turn, suggest that hypoxic attenuation of NO-induced vasodilatation must involve either a decreased abundance, or a decrease in the specific activity, of soluble guanylate cyclase.
Measurements of the absolute abundance of soluble guanylate cyclase revealed no significant effect of chronic hypoxia in either fetal or adult cerebral arteries (Fig. 3, top) . In contrast, soluble guanylate cyclase abundance was ϳ10-fold greater in fetal than adult arteries, indicating that the large age-related differences observed in tissue soluble guanylate cyclase velocity (Fig. 2) were attributable mainly to differences in enzyme abundance. This finding was consistent with previous studies (4, 60) and suggests strong maturational regulation of soluble guanylate cyclase expression. A broad variety of mechanisms have been shown to regulate soluble guanylate cyclase expression, including elevated cAMP (44) , feedback regulation by NO (16, 55) , increased endothelin-1 (37) or heat shock protein 90 (HSP90) (65), increased dehydroepiandrosterone (42), and even RGD-integrin interactions (14) , although which, if any, of these mechanisms contributes to maturational changes in soluble guanylate cyclase expression remains largely unexplored. These factors may also help mediate short-term hypoxic increases in soluble guanylate cyclase expression reported in rat pulmonary arteries (30, 31) . Long-term or chronic hypoxia, however, appears to enable normalization of vascular soluble guanylate cyclase abundance (26) , which helps explain why chronic hypoxia had no effects on soluble guanylate cyclase abundance in either our fetal or adult cerebral arteries (Fig. 3,  top) .
To examine the possible effects of chronic hypoxia on the specific activity of soluble guanylate cyclase, the maximal Fig. 4 . Effects of chronic hypoxia on cGMP degradation in whole artery segments. Artery segments were precontracted with 3 M serotonin and frozen at various times following exposure to 10 M SNAP in the presence (filled symbols) or absence (open symbols) of 300 M IBMX to inhibit phosphodiesterase activity, then assayed for cGMP content. The ⌬ symbol indicates the net difference in rates of cGMP accumulation measured in the presence and absence of IBMX. Although chronic hypoxia tended to depress rates of cGMP degradation in both age groups, this effect was not statistically significant. Vertical error bars indicate SEs for the number of animals indicated for each group. tissue velocities measured in homogenates were normalized relative to absolute soluble guanylate cyclase abundance. The resulting estimates of specific activity eliminated all agerelated differences in soluble guanylate cyclase activity, confirming that differences in abundance were responsible for the observed differences in maximal tissue velocity (Fig. 3, bottom) . More importantly, the specific activity estimates revealed a significant hypoxic decrease in both fetal and adult arteries. Although effects of chronic hypoxia on the specific activity of vascular soluble guanylate cyclase have not been reported previously, our normoxic values of specific activity (200 -300 pmol cGMP ⅐ min Ϫ1 ⅐g sGC
Ϫ1
) corresponded well with previously published values, which ranged from 100 to 700 pmol ⅐min Ϫ1 ⅐g sGC Ϫ1 (17, 23, 29, 41) . This agreement validated our homogenate preparation that included addition of reconstituted heme (60) . Although hypoxia can significantly alter the availability of free iron (33) , the addition of reconstituted heme eliminated this mechanism as a possible explanation for chronic hypoxia's effects on soluble guanylate cyclase specific activity (35) . It remains possible that chronic hypoxia could have modulated the levels of coactivators of soluble guanylate cyclase, including HSP90 (58), carbon monoxide from heme oxygenase (10) , or an as yet unidentified heat stable activator (66) . Alternatively, chronic hypoxia may have promoted posttranslational modification of soluble guanylate cyclase through phosphorylation (40) or ADP-ribosylation (56) . Given the sensitivity of soluble guanylate cyclase to changes in redox state (19, 25) , hypoxic attenuation of specific activity could also reflect redox changes that are characteristic of hypoxic tissues and help mediate increases in hypoxia-inducible factor concentration (11) . Aside from the many unexplored potential mechanisms through which chronic hypoxia might act, the results clearly indicate that chronic hypoxic depression of NO-induced vasorelaxation was mediated by attenuation of the specific activity of cerebrovascular soluble guanylate cyclase.
Aside from effects on guanylate cyclase, chronic hypoxia might also depress reactivity to NO by increasing cGMP phosphodiesterase activity (27) . To explore this possibility, rates of cGMP degradation were determined through measurements of the rates of cGMP accumulation in the presence and absence of the phosphodiesterase inhibitor, IBMX, as previously described (61) . Whereas many studies have examined the effects of hypoxia on vascular phosphodiesterase activity through indirect measurements of the effects of phosphodiesterase inhibitors on vasorelaxation (20, 26, 50) , relatively few have directly calculated phosphodiesterase activity. In a study of rat pulmonary arteries, Murray et al. (39) found that 14 days of chronic hypoxia increased several forms of phosphodiesterase and their activities, including PDE5, which preferentially metabolizes cGMP. In contrast, chronic hypoxia tended to decrease cGMP phosphodiesterase activity in our ovine cerebral arteries, although not significantly (Fig. 4) . This inconsistency with the Murray study may reflect species or artery-toartery differences, which can be substantial (39) , or may simply reflect vascular adaptation to long-term or chronic hypoxia (5) . Either way, the data argue against increases in cGMP phosphodiesterase activity as a mechanism whereby chronic hypoxia depresses reactivity to NO (Fig. 1) .
One final effect through which chronic hypoxia could attenuate NO-induced relaxation would be through inhibition of the vasorelaxant activity of protein kinase G, which is the main intracellular effector of increased cGMP (22) . Studies in porcine (5) and rat (26) pulmonary arteries have reported observations that indirectly suggest chronic hypoxia might decrease protein kinase G vasorelaxant activity. To directly test this possibility, precontracted cerebral arteries were treated with graded concentrations of 8-pCPT-cGMP, a potent and highly selective, cell-permeant, nonhydrolyzable analog of cGMP (8) . Relaxation responses to 8-pCPT-cGMP were not significantly influenced by chronic hypoxia in either fetal or adult cerebral arteries (Fig. 5) . Consistent with studies in rat lung (12) , the relaxant potency of 8-pCPT-cGMP was significantly greater in fetal (pD 2 ϭ 4.7) than adult (pD 2 ϭ 4.3) arteries (Fig. 5,  insets) , suggesting developmental regulation of protein kinase G activity. Nonetheless, the absence of a significant effect of chronic hypoxia on relaxation responses to 8-pCPT-cGMP suggests that changes in protein kinase G activity do not play a major role in hypoxic attenuation of NO-induced relaxation. In summary, the present studies support the general view that chronic hypoxia attenuates vasorelaxation responses to NO and extend this observation to the cerebral circulation. The results reveal that this effect is attributable to attenuation of the specific activity of soluble guanylate cyclase activity and does not involve significant changes in soluble guanylate cyclase abundance, cGMP-phosphodiesterase activity, or the vasorelaxant activity of protein kinase G. These findings emphasize that in addition to the widely reported effects in the pulmonary circulation (1, 13, 54) , chronic hypoxia also modulates vascular reactivity in the cerebral circulation, and probably other vascular beds as well. These generalized vascular effects of chronic hypoxia are quite different from the effects of acute hypoxia and should be carefully considered when designing treatments for chronically hypoxic infants, particularly those at risk for intracranial hemorrhage (21, 51) . From a basic science perspective, these results also raise many additional questions. For example, at what postnatal age does the main decrease in soluble guanylate cyclase activity occur? Are the changes in soluble guanylate cyclase activity observed in response to maturation and chronic hypoxia similar in large and small arteries, or do vessels of the microcirculation exhibit a unique pattern of changes in soluble guanylate cyclase activity? To what extent are the effects of chronic hypoxia on soluble guanylate cyclase activity attributable to the actions of hypoxia-inducible factor (52) and/or vascular endothelial growth factor (6)? Most importantly, what is the physiological significance of the changes in soluble guanylate cyclase activity induced by chronic hypoxia and postnatal development, and do these changes provide some adaptive advantage or are they merely consequences of more general metabolic and endocrine responses? Clearly, the regulatory importance of soluble guanylate cyclase and the NO/cGMP/protein kinase G pathway suggests that exploration of the mechanisms whereby chronic hypoxia attenuates the specific activity of soluble guanylate cyclase could both expand basic understanding of how hypoxia modulates vascular contractility as a function of developmental age and thereby could also hasten the development of new therapeutic strategies for clinical treatment and management of hypoxic neonates.
